| Identification | Back Directory | [Name]
ICI 89406 | [CAS]
53671-71-9 | [Synonyms]
C025716
ICI 89406
N-[2-[3-(2-CYANOPHENOXY)-2-HYDROXYPROPYLAMINO]ETHYL]-N'-PHENYLUREA
Urea, N-(2-((3-(2-cyanophenoxy)-2-hydroxypropyl)amino)ethyl)-N'-phenyl- | [Molecular Formula]
C19H22N4O3 | [MDL Number]
MFCD00673934 | [MOL File]
53671-71-9.mol | [Molecular Weight]
354.4 |
| Chemical Properties | Back Directory | [Melting point ]
155-156 °C(Solv: acetonitrile (75-05-8)) | [Boiling point ]
575.0±50.0 °C(Predicted) | [density ]
1.25±0.1 g/cm3(Predicted) | [storage temp. ]
Store at RT | [solubility ]
Soluble in ethanol and to 100 mM in DMSO | [form ]
Powder | [pka]
12.29±0.46(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
ICI 89406 is beta-1-selective antagonist. | [Definition]
ChEBI: 1-[2-[[3-(2-cyanophenoxy)-2-hydroxypropyl]amino]ethyl]-3-phenylurea is a member of ureas. | [Biological Activity]
β -adrenergic antagonist and low efficacy partial agonist; does not affect resting cardiac parameters. | [in vivo]
| Animal Model: | Rats[2]. | | Dosage: | 0.6, 5 or 50 mg/kg. | | Administration: | Orally (5 or 50 mg/kg), i.p. (5 mg/kg), i.v. 0.6 (0.6 mg/kg) (Pharmacokinetic Analysis). | | Result: | Following oral administration, the dose of 5 mg/kg urinary and faecal excretion accounted for 5.8 + 0.7% and 96.4 + 2.1%. The dose of 50 mg/kg urinary and faecal excretion accounted for 14.0 + 4.0% and 78.4 + 2.4%. The proportions of unchanged drug and metabolites in urine were independent of the dose. The unchanged drug accounted for 81.6% of the faecal components after a dose of 5 mg/kg but this was reduced to 47.8%. |
| [storage]
Store at RT |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|